Abstract:Background: Neuroendocrine breast carcinoma (NECB) is a rare, special histologic type of breast cancer. There are some small sample studies on the clinical outcomes of NECB patients, which are worthy of further discussion. Methods: We conducted a retrospective case-control study of clinical characteristics and outcomes among patients with primary NECB versus invasive carcinoma of no special type (NST) between November 2004 and November 2017 in the Peking Union Medical College Hospital, Beijing. NST patients were strictly matched 1:4 during the same period based on the TNM stage. Statistical comparisons were performed to determine the differences in survival between NST and NECB patients and to identify clinical factors that correlate with prognosis. Results: A total of 121 participants affected by primary NECB were included in our analysis from November 2004 to November 2017. Elderly persons (>60 years of age) were more likely to have primary NECB than young persons (p=0.001). In addition, primary NECB patients had significantly higher odds of having tumors 2-5 cm (36.5%) and >5 cm (6.1%) in size than NST patients. Despite a significant difference in tumor size, the proportion of patients with lymph node metastases showed no difference between the two groups (p=0.021). In addition, the rate of patients with ER-negative tumors in the NECB group (4.2%) was significantly lower than that in the primary NST group (29.8%). Significant differences were noted in the PR-negative (13.3% versus 36.6%, P<0.001) and HER2-negative (90.5% versus 76.4%, P=0.001) expression statuses among these patients. Of 121 primary NECB patients, 11 (9.1%) experienced relapses during the follow-up period. We found that tumor size was an independent risk factor for relapse. For hormone receptors on tumor cells, ER-positive breast cancer patients had significantly lower odds of relapse than receptor-negative patients. Conclusions: Our data demonstrate no significant difference in mortality and relapse between the primary NECB and NST groups. The tumor size in the primary NECB group was significantly larger than that in the NST group. In addition, the absence of ER independently increased the relapse rate for breast carcinoma patients.

Prognostic factors of primary neuroendocrine breast cancer: A population‐based study

Clinical Prognostic Factors for Central Neurocytoma and Subgroup Analysis of Different Treatment Measures: A SEER Database-Based Retrospective Analysis from 2003 to 2019

Primary Neuroendocrine Breast Carcinomas: A Retrospective Analysis and Review of Literature

Invasive Neuroendocrine Carcinoma of the Breast: A Prognostic Research of 107 Chinese Patients

Clinicopathological Features And Prognostic Factors Of Colorectal Neuroendocrine Neoplasms

[Study on Clinicopathologic Grading System and Prognosis of Primary Hepatic Neuroendocrine Neoplasms].

Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study

Primary Neuroendocrine Carcinoma of the Breast: Mammographic, Ultrasound, and Magnetic Resonance Imaging Findings

Prognostic Significance of Tumor Grading and Staging in Mammary Carcinomas with Neuroendocrine Differentiation

Nomogram Predicted Overall Survival of Patients with Neuroendocrine Carcinoma of the Breast

Neuroendocrine Carcinoma of the Breast is More Aggressive Than Breast Invasive Ductal Carcinoma: A Propensity Score Matching Study Based on SEER Database

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study

Comparison of clinical characteristics and outcomes in primary neuroendocrine breast carcinoma versus invasive ductal carcinoma

Low-serum Prostate-Specific Antigen Level Predicts Poor Outcomes in Patients with Primary Neuroendocrine Prostate Cancer.

Prognostic Factors and Survival in Patients with Neuroendocrine Tumors of the Pancreas

Pathological types affect survival outcomes in patients with surgically treated high-grade neuroendocrine carcinoma of the cervix: A multicenter, retrospective study

Clinical and Pathologic Analysis of 11 Cases of Primary Breast Neuroendocrine Carcinoma

Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center.

Prognostic Factors and Treatment Comparison in Small Cell Neuroendocrine Cervical Carcinoma.

Identification and initial validation of neuroendocrine differentiation as a novel prognostic factor in stage II colorectal cancer patients